Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
about
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsThe role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaSignaling in Effector Lymphocytes: Insights toward Safer ImmunotherapyPotential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Novel immunotherapies in lymphoid malignanciesNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyCD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaImmunotherapy of Childhood SarcomasMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesMonoclonal antibodies in acute lymphoblastic leukemiaHigh-content molecular profiling of T-cell therapy in oncologyImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteBlinatumomab for lymphoblastic leukaemiaCatch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesSecond- and third-generation ALK inhibitors for non-small cell lung cancerToxicity and management in CAR T-cell therapyClinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adultsSecond-generation inhibitors of Bruton tyrosine kinaseRecent advances and novel treatment paradigms in acute lymphocytic leukemiaEmerging Therapies for Rheumatoid ArthritisAdvancements in Therapy for Acute Lymphoblastic Leukemia: BlinatumomabCAR therapy: the CD19 paradigmThe Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and RiskDiscovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.Burkitt lymphoma in adolescents and young adults: management challenges.Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Antibody Therapies in Cancer.Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Immunotherapy in hematologic malignancies: past, present, and future.Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.Clinical Pharmacology and Translational Aspects of Bispecific AntibodiesCentral Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell TransplantationThe biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.
P2860
Q26738729-7346117B-22BE-4C29-8A13-6148542F3234Q26744280-85A3841E-2F25-458B-A759-807097376F71Q26744654-DBB3D042-6E5D-43AA-BA1F-B172D4F332D1Q26764903-0B9EF760-96A8-4D03-8D29-9781269610FEQ26768154-06055F82-6F65-42BF-810F-82A513716CA2Q26770391-958FB2AF-DD94-4A95-A25D-EE575F7B6DCCQ26777394-74604B5E-57A0-4345-B677-F197EA259F31Q26782270-D71E1B50-EBDB-441E-B3D0-04C8AFA3763FQ26783433-C883BB5D-3B0C-4EFE-B028-08A464419594Q26785828-A4161AC5-FF6A-4DAB-9077-CA6159D54497Q26795369-0E506F06-02E9-4327-8CBF-76426B866614Q26828511-6FECD825-AE6B-49CB-B2AD-9170F3A812F9Q26865838-A051EFC6-54C0-450D-94E0-5870719AC10DQ27022540-CF0CCCFE-E745-4DCB-8DCE-B4E08C20DBB6Q28066792-E071CB42-CA47-47B6-8F5B-B355BB20DE9AQ28066935-8A3E10CB-3F45-49FD-B1EC-5845AFB4D20CQ28069914-1C8FB006-76DC-4F56-95A1-187454A3B5FEQ28072131-D0163AD2-27BD-4851-941D-57A325462F98Q28072496-CC7F045B-A39C-47C4-81F9-15E7EEF5CF9DQ28075314-A2251122-AE0F-4FD1-BBCB-3C46F7B168B0Q28075764-B233F43E-D6A7-4A09-AD7C-09956F40374AQ28076118-14FBD345-017E-4575-AD38-97E02425ED20Q28078076-10E74FD9-6422-42FB-A488-475FE0B19A1AQ28078943-7080B3E1-93FE-4230-AD40-6290320F7AA0Q28079934-C28DBC39-22B9-4C33-B783-D31A3F35895FQ28081642-14D2527A-7208-4CEC-829C-5061B44FA6FDQ28547458-B8E8732B-0A35-4603-A17C-D851FD4A4F81Q30009098-969A2D69-87FB-4F27-A68F-A570DC501193Q30238965-90B619C6-CE14-4270-9B2B-994EDAAE73F6Q30240892-BB0B2615-A552-44C2-9169-029499C74067Q30243925-9826F60D-DC2B-4CCD-9EFE-0AD1CAEEB4AEQ31104000-510CB15C-EB99-449C-A0C3-4A8582EC43DAQ31143912-31B4E182-0B23-47F0-9B3B-8D4CA8A7CA62Q33433407-A2BE5290-7997-434F-8FF5-22080ACCF31CQ33564645-4E75B557-A775-4B39-B1AC-79B0E073BED3Q33593865-2EC4EA4B-FF8A-48EB-B495-C1B8B9A9F015Q33600768-30135D0F-0147-437A-BC67-C1383FECB292Q33648086-A29CD87C-9CDD-4B67-8833-765F1EF97D32Q33679931-707C2A5C-1F04-4E54-94C6-A94C4C3B134EQ33698398-762CD167-D020-4091-976A-F4E09DFC354A
P2860
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@ast
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@en
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@nl
type
label
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@ast
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@en
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@nl
prefLabel
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@ast
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@en
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@nl
P2093
P50
P1433
P1476
Safety and activity of blinatu ...... re, single-arm, phase 2 study.
@en
P2093
Adele K Fielding
Alessandro Rambaldi
Anthony S Stein
Birgit Huber
Catherine Jia
Chris Holland
Dirk Nagorsen
Gary Schiller
Gerhard Zugmaier
Heinz A Horst
P356
10.1016/S1470-2045(14)71170-2
P577
2014-12-16T00:00:00Z